Aarey Drugs Q4 Results FY26: Revenue, PAT, Net Profit and Key Highlights

Aarey Drugs Q4 results for the quarter ended March 2026 show revenue of Rs 189 crore (+75% year on year) and net profit of Rs 2 crore (Turnaround year on year). Reported on a Standalone basis, these numbers reflect Aarey Drugs’s core Pharmaceuticals performance through Q4 FY25-26. This article covers the full financial breakdown, margin analysis, and FY27 outlook to help investors make informed decisions about Aarey Drugs.

Click Here – Get Free Investment Predictions

Aarey Drugs Q4 FY26 Financial Highlights

The table below summarises key financial metrics comparing Q4 FY26 with Q4 FY25 on a Standalone basis.

Detailed Analysis of Aarey Drugs Q4 Results

Check the Univest Screener for live Aarey Drugs data

Revenue grew to Rs 189 crore in Q4 FY26 from Rs 108 crore in the year-ago quarter, a +75% change year on year. The Pharmaceuticals segment drove the top line through this period, with demand conditions and pricing realisations shaping the quarterly revenue outcome. Investors tracking Aarey Drugs Q4 results are watching whether this revenue run rate sustains into FY27.

Gross profit stood at Rs 3 crore at a margin of 1.6%, compared to Rs -3 crore and -2.8% in Q4 FY25. The gross margin movement reflects input cost dynamics and product mix across Aarey Drugs’s operations. Ankit Jaiswal, Senior Research Analyst at Univest, notes that margin outcomes in the Pharmaceuticals sector are sensitive to commodity cost cycles that played out through Q4 FY26.

Net profit rose to Rs 2 crore from Rs 0 crore in Q4 FY25. At a PAT margin of 1.1%, the earnings quality reflects how efficiently Aarey Drugs is converting revenue to bottom-line income. Ankit Jaiswal highlights that the Aarey Drugs Q4 results set a key profitability baseline for assessing FY27 earnings potential.

Key Business Factors in Q4 FY26

Revenue Drivers and Volume Trends

The +75% revenue change to Rs 189 crore in Q4 FY26 reflects Aarey Drugs’s demand conditions and order execution in the Pharmaceuticals space. Volume performance, customer mix, and realisation per unit each contributed to the quarterly top-line figure. Whether this revenue level is sustainable into FY27 remains a key question for investors tracking the stock.

Gross Margin and Cost Management

A gross margin of 1.6% in Q4 FY26 reflects Aarey Drugs’s cost management posture within the Pharmaceuticals segment. Input cost trends, freight expenses, and production efficiencies shaped this outcome. Sustaining or improving gross margins into FY27 will depend on Aarey Drugs’s ability to control costs as revenue scales through the year.

Profitability and Earnings Quality

Net profit of Rs 2 crore at a 1.1% PAT margin reflects Aarey Drugs’s earnings conversion in Q4 FY26. Finance costs, tax provisions, and non-operating items all influence the final PAT figure. The repeatability of these earnings will be central to how the company is valued heading into FY27.

Dividend Details

Aarey Drugs has not announced any dividend for Q4 FY26 as per information available on May 30, 2026. Investors should track official BSE/NSE filings for any board-level decisions on dividends or capital return for the full financial year FY26.

FY27 Outlook

Aarey Drugs enters FY27 with a revenue base of Rs 189 crore and net profit of Rs 2 crore from the Aarey Drugs Q4 results. The Pharmaceuticals sector’s FY27 trajectory depends on domestic demand, input cost stability, and any regulatory changes that affect the broader operating environment.

Ankit Jaiswal suggests that investors tracking Aarey Drugs should monitor quarterly management guidance, order book updates, and margin improvement milestones closely through H1 FY27. The transition from Aarey Drugs Q4 results into a full-year FY27 delivery is a critical inflection point for long-term shareholders in the stock.

Aarey Drugs Stock Performance

Download the Univest Android App or Univest iOS App to track Aarey Drugs share price and get daily research updates.

Aarey Drugs shares are trading at Rs 76.0 as of May 30, 2026. The stock’s reaction to Aarey Drugs Q4 results reflects how the market is assessing the company’s performance relative to Pharmaceuticals sector expectations. Live price data, technical analysis, and research coverage for Aarey Drugs are available on the Univest platform.

Key Risks for Aarey Drugs

Pharmaceuticals Sector Headwinds

The Pharmaceuticals industry faces risks from commodity price swings, regulatory shifts, and competitive pressure. Any deterioration in sector fundamentals could weigh on Aarey Drugs’s revenue and margin outlook beyond Q4 FY26 levels.

Macroeconomic and External Risks

Global growth concerns, FII outflows, and domestic inflation pressures pose risks to Aarey Drugs’s valuation multiples independent of operational performance. A weak demand environment or rising interest rates could compress near-term earnings.

Execution and Working Capital Risk

Sustaining Q4 FY26 revenue and profitability levels into FY27 requires consistent execution from Aarey Drugs’s management. Receivable elongation, working capital build-up, or unexpected capex commitments could pressure future quarterly cash flows and earnings quality.

Conclusion

Aarey Drugs Q4 results for Q4 FY26 show revenue of Rs 189 crore and net profit of Rs 2 crore, establishing a clear picture of the company’s financial position in the Pharmaceuticals space. The +75% revenue change and Turnaround PAT movement provide a meaningful baseline for FY27 projections. Ankit Jaiswal recommends that investors review these numbers alongside sector trends and management commentary before making any investment decisions related to Aarey Drugs.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Frequently Asked Questions on Aarey Drugs Q4 FY26 Results

When were the Aarey Drugs Q4 results announced?

Ans. The Q4 FY26 results for Aarey Drugs were declared on May 30, 2026, covering the quarter ended March 2026.

What was the revenue in Aarey Drugs Q4 results?

Ans. Aarey Drugs reported revenue of Rs 189 crore in Q4 FY26, compared to Rs 108 crore in Q4 FY25, a change of +75% year on year.

What was the net profit in Aarey Drugs Q4 results?

Ans. Aarey Drugs reported a net profit (PAT) of Rs 2 crore in Q4 FY26, compared to Rs 0 crore in Q4 FY25, a Turnaround change year on year.

What is the FY27 outlook after Aarey Drugs Q4 results?

Ans. Aarey Drugs enters FY27 with revenue of Rs 189 crore and PAT of Rs 2 crore as a baseline. The FY27 outlook depends on Pharmaceuticals demand, cost management, and execution quality.

Did Aarey Drugs declare a dividend after Aarey Drugs Q4 results?

Ans. No dividend was declared for Q4 FY26 as per information available on May 30, 2026. Investors should check official exchange filings for any board announcements on capital returns.

How did Aarey Drugs shares react to Aarey Drugs Q4 results?

Ans. Aarey Drugs shares are trading at Rs 76.0 as of May 30, 2026. The stock movement post-results reflects market assessment of the quarterly earnings against Pharmaceuticals sector expectations.

Should investors buy Aarey Drugs shares based on Aarey Drugs Q4 results?

Ans. Investment decisions should factor in the full Q4 FY26 financials for Aarey Drugs, FY27 growth outlook, current valuation, and personal risk profile. Always consult a SEBI-registered investment adviser before investing.

What risks should investors watch after Aarey Drugs Q4 results?

Ans. Key risks for Aarey Drugs include Pharmaceuticals sector headwinds, macroeconomic uncertainty, input cost volatility, and working capital pressure. Investors should track quarterly updates and management commentary to assess the risk-reward profile for the stock in FY27.